Endovascular approach to recanalize large vessel occlusions in ischaemic stroke patients was recently shown to be associated with improved clinical outcomes. This has revolutionized the field because until recently intravenous thrombolytic therapy was the only proven therapy available to treat these patients.
Endovascular therapy, either in addition to iv thrombolysis, or alone if patient has contradiction to iv thrombolysis, is now recommended as the treatment of choice for ischaemic stroke patients with large vessel occlusions. The stroke centers across the globe are incorporating lessons learnt from these trials and the ongoing registries in providing care to these patients. With this end in perspective, we welcome manuscripts examining the endovascular trials that investigated the hyper acute stroke therapy and inform our readership about the system of care that could be relevant to their settings. We also welcome view points on trial design issues as there still are unanswered questions with respect to optimal outcome analyses, the use of time as criterion for patient selection, and the natural history of disease. Further, there is a growing need to identify patients most likely to benefit from these therapeutic approaches, and we wish to educate our readership about approaches to identify these patients.
Endovascular approach to recanalize large vessel occlusions in ischaemic stroke patients was recently shown to be associated with improved clinical outcomes. This has revolutionized the field because until recently intravenous thrombolytic therapy was the only proven therapy available to treat these patients.
Endovascular therapy, either in addition to iv thrombolysis, or alone if patient has contradiction to iv thrombolysis, is now recommended as the treatment of choice for ischaemic stroke patients with large vessel occlusions. The stroke centers across the globe are incorporating lessons learnt from these trials and the ongoing registries in providing care to these patients. With this end in perspective, we welcome manuscripts examining the endovascular trials that investigated the hyper acute stroke therapy and inform our readership about the system of care that could be relevant to their settings. We also welcome view points on trial design issues as there still are unanswered questions with respect to optimal outcome analyses, the use of time as criterion for patient selection, and the natural history of disease. Further, there is a growing need to identify patients most likely to benefit from these therapeutic approaches, and we wish to educate our readership about approaches to identify these patients.
